Pritesh Mehta
Beth Israel Deaconess Medical Center
17 Papers
76 Citations
Pritesh Mehta is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Medicine & Engineering. The author has an hindex of 7, co-authored 12 publications. Previous affiliations of Pritesh Mehta include Yale University.
Chat about Author
Papers
Racial disparities in clinical and economic outcomes from thyroidectomy.
TL;DR: It is suggested that, although thyroidectomy is considered safe, significant racial disparities exist in clinical and economic outcomes and inequalities result from racial differences in access to experienced surgeons.
177
A Population-Based Study of Outcomes from Thyroidectomy in Aging Americans: At What Cost?
TL;DR: Clinical and economic outcomes for patients 65 years and older undergoing thyroidectomies are considerably worse than for similar, younger patients, and increased referrals to high-volume surgeons for aging Americans are necessary.
167
The maturation of a specialty: Workforce projections for endocrine surgery
Julie Ann Sosa,Tracy S. Wang,Heather L. Yeo,Pritesh Mehta,Leon Boudourakis,Robert Udelsman,Sanziana A. Roman +6 more
TL;DR: Surgeon supply is projected to increase to 938 by 2020; this is based on fellowship graduation rates, retirement trends, and increasing annual endocrine case volume among high-volume surgeons.
75
Medullary thyroid cancer: early detection and novel treatments.
TL;DR: Several recent advances in the diagnosis, molecular biology, imaging, and treatment options of MTC are reviewed, potentially downstaging of disease, and treating metastatic disease more effectively, so that overall survival and outcomes of patients may improve.
48
To Stimulate or Withdraw? A Cost-Utility Analysis of Recombinant Human Thyrotropin Versus Thyroxine Withdrawal for Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer in the United States
TL;DR: In the United States, the cost-effectiveness of rhTSH for ablation in patients with low-risk differentiated thyroid cancer is highly dependent on potential variations in cost of rh TSH, rates of remnant ablation, time off work, and quality of life.
41